• Mesoblast Ltd., of Melbourne, Australia, said its Phase II trial for lumbar spinal fusion met its safety and efficacy endpoints, with results suggesting that NeoFuse, its product comprising allogeneic mesenchymal precursor cells (MPCs), is as effective for interbody lumbar fusion as bone autograft without the need for a second surgical procedure and its attendant morbidity risks.